Clinical trial
E3 Breast Cancer Taxotere Combination
NCT00494481 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00494481 |
|---|---|
| Title | E3 Breast Cancer Taxotere Combination |
| Official title | A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC). |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib (ZD6474), Docetaxel |
| Enrollment | 64 |
| Start date | Jan 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Jun 29, 2007 |
| Last update posted | Sep 30, 2016 |
| Countries | Hungary, South Africa, Spain, Sweden, Taiwan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: